Prostate Cancer
Abiraterone With Or Without ABT-888 For Metastatic Castration-Resistant Prostate Cancer (7847)
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01576172
A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy
Investigator: Evan Yu, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01253642
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer
Investigator: Robert Bruce Montgomery, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01508234
A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01703065
Open Label Pharmacodynamic Study of Abiraterone in the Treatment of Metastatic, Castration Resistant Prostate Cancer
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01503229
A PhaseI/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01106352
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Investigator: Celestia S. Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01188187
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Investigator: ; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01615120
A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP30862 in Patients with Metastatic Castration-Resistant Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01283373
A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy (RTOG 0534)
Investigator: George Laramore, MD, PhD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00567580
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Investigator: ; Conditions: Metastatic Prostate Cancer; Status: Recruiting; Study ID: NCT01385293
Degarelix Acetate Prior to Radiation Therapy
Investigator: Robert Bruce Montgomery, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01731912
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Investigator: Celestia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01685489
An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer
Investigator: Celestia S. Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT01171898
Molecular correlates of sensitivity and resistance to therapy in prostate cancer
Investigator: Robert Montgomery, MD; Conditions: Metastatic Prostate Cancer; Status: Recruiting; Study ID: NCT01050504
Canary Prostate Active Surveillance Study
Investigator: Daniel W. Lin, MD; Conditions: Prostatic Neoplasms; Status: Recruiting; Study ID: NCT00756665
SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients
Investigator: Monique Cherrier, PhD; Conditions: Prostate Cancer; Status: Recruiting
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Investigator: Tia Higano, MD; Conditions: Prostate Cancer; Status: Recruiting; Study ID: NCT00488982
Phase 2 Trial of Radiation with Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent with Radiation Therapy.
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer, Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer; Status: Recruiting; Study ID: NCT01023061
A Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, or No MLN8237 in Patients with Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen, Preceded by a Phase I Dose-Escalation Study - Part 1 and 2
Investigator: Tia Higano, MD; Conditions: Genitourinary Cancer; Prostate Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01094288
A Phase 2 Assessment of the Diagnostic Accuracy of Tc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy and Extended Pelvic Lymph Node Dissection Compared to Histopathology
Investigator: William Ellis; Conditions: Rectal Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01667536
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED)
Investigator: Celestia Higano, MD; Conditions: Advanced Prostate Cancer; Status: Recruiting; Study ID: NCT01306890
Phase II Trial of Abiraterone Acetate Combined with Dutasteride with Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Signaling in Patients with Metastatic Castrate Resistant Prostate Cancer (CRPC)
Investigator: Robert Montgomery, MD; Conditions: Prostate Cancer; Status: Closed; Study ID: NCT01393730
Join Us On